324 related articles for article (PubMed ID: 29771386)
1. Immunotherapy in CNS cancers: the role of immune cell trafficking.
Ratnam NM; Gilbert MR; Giles AJ
Neuro Oncol; 2019 Jan; 21(1):37-46. PubMed ID: 29771386
[TBL] [Abstract][Full Text] [Related]
2. The CNS and the Brain Tumor Microenvironment: Implications for Glioblastoma Immunotherapy.
Desland FA; Hormigo A
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027976
[TBL] [Abstract][Full Text] [Related]
3. Harnessing the immune system in glioblastoma.
Brown NF; Carter TJ; Ottaviani D; Mulholland P
Br J Cancer; 2018 Nov; 119(10):1171-1181. PubMed ID: 30393372
[TBL] [Abstract][Full Text] [Related]
4. Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity.
Grabovska Y; Mackay A; O'Hare P; Crosier S; Finetti M; Schwalbe EC; Pickles JC; Fairchild AR; Avery A; Cockle J; Hill R; Lindsey J; Hicks D; Kristiansen M; Chalker J; Anderson J; Hargrave D; Jacques TS; Straathof K; Bailey S; Jones C; Clifford SC; Williamson D
Nat Commun; 2020 Aug; 11(1):4324. PubMed ID: 32859926
[TBL] [Abstract][Full Text] [Related]
5. Innovative and Promising Strategies to Enhance Effectiveness of Immunotherapy for CNS Tumors: Where Are We?
Quintarelli C; Camera A; Ciccone R; Alessi I; Del Bufalo F; Carai A; Del Baldo G; Mastronuzzi A; De Angelis B
Front Immunol; 2021; 12():634031. PubMed ID: 34163465
[TBL] [Abstract][Full Text] [Related]
6. Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment.
Widodo SS; Hutchinson RA; Fang Y; Mangiola S; Neeson PJ; Darcy PK; Barrow AD; Hovens CM; Dinevska M; Stylli SS; Mantamadiotis T
Cancer Immunol Immunother; 2021 Jul; 70(7):1811-1820. PubMed ID: 33389014
[TBL] [Abstract][Full Text] [Related]
7. A Window of Opportunity: Targeting Cancer Endothelium to Enhance Immunotherapy.
Duru G; van Egmond M; Heemskerk N
Front Immunol; 2020; 11():584723. PubMed ID: 33262763
[TBL] [Abstract][Full Text] [Related]
8. Glioblastoma antigen discovery--foundations for immunotherapy.
Azad TD; Razavi SM; Jin B; Lee K; Li G
J Neurooncol; 2015 Jul; 123(3):347-58. PubMed ID: 26045361
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract][Full Text] [Related]
10. Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.
Mukaida N; Nakamoto Y
World J Gastroenterol; 2018 May; 24(17):1839-1858. PubMed ID: 29740200
[TBL] [Abstract][Full Text] [Related]
11. Advances in Nanotechnology-Based Immunotherapy for Glioblastoma.
Tang L; Zhang M; Liu C
Front Immunol; 2022; 13():882257. PubMed ID: 35651605
[TBL] [Abstract][Full Text] [Related]
12. Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.
Pearson JRD; Cuzzubbo S; McArthur S; Durrant LG; Adhikaree J; Tinsley CJ; Pockley AG; McArdle SEB
Front Immunol; 2020; 11():582106. PubMed ID: 33178210
[TBL] [Abstract][Full Text] [Related]
13. Central nervous system tumor immunity generated by a recombinant listeria monocytogenes vaccine targeting tyrosinase related protein-2 and real-time imaging of intracranial tumor burden.
Prins RM; Bruhn KW; Craft N; Lin JW; Kim CH; Odesa SK; Miller JF; Liau LM
Neurosurgery; 2006 Jan; 58(1):169-78; discussion 169-78. PubMed ID: 16385341
[TBL] [Abstract][Full Text] [Related]
14. Immune Microenvironment Landscape in CNS Tumors and Role in Responses to Immunotherapy.
Najem H; Khasraw M; Heimberger AB
Cells; 2021 Aug; 10(8):. PubMed ID: 34440802
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model.
Mathios D; Park CK; Marcus WD; Alter S; Rhode PR; Jeng EK; Wong HC; Pardoll DM; Lim M
Int J Cancer; 2016 Jan; 138(1):187-94. PubMed ID: 26174883
[TBL] [Abstract][Full Text] [Related]
16. Exploitation of immune mechanisms in the treatment of central nervous system cancer.
Pollack IF; Okada H; Chambers WH
Semin Pediatr Neurol; 2000 Jun; 7(2):131-43. PubMed ID: 10914414
[TBL] [Abstract][Full Text] [Related]
17. The Tumor Immune Microenvironment in Primary CNS Neoplasms: A Review of Current Knowledge and Therapeutic Approaches.
Kalluri AL; Shah PP; Lim M
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768342
[TBL] [Abstract][Full Text] [Related]
18. Reversing Epigenetic Gene Silencing to Overcome Immune Evasion in CNS Malignancies.
Ratnam NM; Sonnemann HM; Frederico SC; Chen H; Hutchinson MND; Dowdy T; Reid CM; Jung J; Zhang W; Song H; Zhang M; Davis D; Larion M; Giles AJ; Gilbert MR
Front Oncol; 2021; 11():719091. PubMed ID: 34336705
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
[TBL] [Abstract][Full Text] [Related]
20. Combination of hyaluronic acid conjugates with immunogenic cell death inducer and CpG for glioblastoma local chemo-immunotherapy elicits an immune response and induces long-term survival.
Catania G; Rodella G; Vanvarenberg K; Préat V; Malfanti A
Biomaterials; 2023 Mar; 294():122006. PubMed ID: 36701998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
